
GEHC Stock Forecast & Price Target
GEHC Analyst Ratings
Bulls say
GE HealthCare Technologies has exhibited a robust growth trajectory indicated by a backlog that is now approximately $1 billion above pre-COVID levels, driven by consistent low-to-mid single-digit order growth and a favorable book-to-bill ratio above 1. The company reported a commendable gross margin of 41.4% in the fourth quarter, exceeding expectations due to improved volumes and a higher mix of new products at advantageous pricing, alongside a notable increase in revenue from the patient diagnostics segment, which surged 24% year-over-year. Additionally, the sustained growth in EBIT margins, which rose by 50 basis points year-over-year to 15.3% in the second quarter of 2024, reflects effective pricing strategies and operational efficiencies, underpinning confidence in the financial stability and future performance of GE HealthCare Technologies.
Bears say
GE HealthCare Technologies has faced notable challenges due to declining sales in China, with year-over-year decreases of approximately 11% and 18% reported in the first and second quarters of 2024 respectively. The company has adjusted its full-year 2024 sales guidance downward by about $500 million to reflect ongoing pressures, including volume-based procurement and reduced capital spending by hospitals in the region. Furthermore, despite a book-to-bill ratio of 1.03 in the third quarter indicating a healthy order intake, the overall top-line performance in the first half of 2024 was negatively impacted, leading to a cautious outlook for the remainder of the year.
This aggregate rating is based on analysts' research of GE HealthCare Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.
GEHC Analyst Forecast & Price Prediction
Start investing in GEHC
Order type
Buy in
Order amount
Est. shares
0 shares